This article has Open Peer Review reports available.
Diagnostic criteria for diabetes revisited: making use of combined criteria
© Parappil et al; licensee BioMed Central Ltd. 2002
Received: 14 November 2001
Accepted: 01 February 2002
Published: 01 February 2002
Existing cut-offs for fasting plasma glucose (FPG) and post-load glucose (2hPG) criteria are not equivalent in the diagnosis of diabetes and glucose intolerance. Adjusting cut-offs of single measurements have not helped so we undertook this project to see if they could be complementary.
We performed oral glucose tolerance tests and mean levels of hemoglobin A1c (HbA1c) measurements on 43 patients referred to a diabetes clinic for possible diabetes. Results of single and combined use of the FPG and 2hPG criteria were evaluated against the levels of HbA1c and results re-interpreted in the light of existing reports in the literature.
Our results confirm that the FPG and the 2hPG, being specific and sensitive respectively for the presence of glucose intolerance or diabetes, are not equivalent. They are shown to be indeed complementary and a re-definition of diagnostic criteria based on their combined use is proposed.
We conclude that altering single measurement cut-offs for the diagnosis of diabetes and altered glucose tolerance will not result in better outcomes. We present the case for a combined criteria in the diagnosis and definition of diabetes with a FPG≥7 mmol/L AND 2-hour glucose ≥7.8 mmol/L being used to define diabetes while a FPG<7 mmol/L AND 2-hour glucose <7.8 mmol/L being used to define normality. Discordant values will define impaired glucose tolerance (IGT). This proposal requires prospective evaluation in a large cohort.
Prior to the National Diabetes Data Group (NDDG) diagnostic criteria for diabetes in 1979, there were many different sets of criteria used to diagnose diabetes  resulting in a prevalence of diabetes that differed depending on the criteria used. In 1979, the NDDG recommended one set of criteria  which was modified by the World Health Organization (WHO)  in 1980. These criteria were selected based on the results of 3 prospective studies [4–6] in which subjects without diabetic retinopathy were given oral glucose tolerance tests and followed for 3 to 8 years, at which time 6% of them had developed this complication . Based on the 2-hour post glucose (2hPG) values of these individuals, a 2-hour glucose concentration of ≥ 11.1 mmol/L and a fasting plasma glucose concentration of ≥ 7.8 mmol/L were established as the criteria for the diagnosis of diabetes. In 1997, the American Diabetes Association (ADA) convened an expert committee to revisit these criteria . The committee lowered the fasting plasma glucose (FPG) concentration for the diagnosis of diabetes from ≥ 7.8 mmol/L to ≥ 7.0 mmol/L but decided to retain the 2-hour value of ≥ 11.1 mmol/L on the oral glucose tolerance test because a large number of epidemiological studies in the literature used this value to define diabetes and changing it "would be very disruptive".
However this 2hPG criterion and the FPG values defined as diagnostic of diabetes by the World Health Organization (WHO)  are not equivalent: approximately three quarters of subjects with diagnostic 2hPG concentrations (≥ 11.1 mmol/L) have fasting glucose values below the level defined as diagnostic by the WHO (7.8 mmol/L). Roughly 75% of subjects who participated in the NHANES II with diagnostic 2-h values had fasting values <7.8 mmol/L. Similarly, in relation to the ADA criteria, there is mounting evidence that there is a sizeable proportion of previously undiagnosed diabetic people with a 2hPG glucose ≥ 11.1 mmol/L but FPG <7.0 mmol/L. This proportion varies in different populations and ranges from 32 to 72%.[10–12] It has also been shown, from pooled analyses of 20 studies conducted in different European countries, that as many as one-third (31%) of those who are diabetic, according to the 2hPG, have normal fasting values (<6.1 mmol/1)  and therefore, would not be detected by a screening procedure based essentially on fasting glucose measurements. In addition, fasting glucose is of little help in diagnosing impaired glucose tolerance (IGT) since evidence is accumulating that most people with IGT (from 54 to 67%) have fasting glucose in the normal range (<6.1 mmol/L).[12–14]
It seems clear therefore, that not only are these cutoffs not equivalent in their definition of diabetes but the increased emphasis given by the expert committee  on the fasting values may not entirely be optimal. One strong argument for this is that it has been demonstrated that isolated post load hyperglycemia is a strong predictor of mortality [10, 15, 16] and progression to diabetes, [13, 14] with prevention of progression to overt diabetes being possible in this group. Based on the data presented above, the fasting criteria alone will be unable to detect this intermediate group of glucose intolerance. This is not just a consequence of the fasting cutoff, since it has also been shown, from the pooled data mentioned above , that even if the fasting glucose threshold is lowered to 5.5 mmol/l, (thus detecting 93% of all those with diabetes diagnosed on the basis of 2hPG), its ability to identify IGT (sensitivity) does not improve substantially. It has therefore been concluded that the FPG, while being useful to confirm the overtly diabetic state, misclassifies many people with abnormal glucose tolerance as being normal . Since the latter group can be picked up by the 2hPG values, and adjustment of the fasting cut-off is of no additional benefit, it makes sense to use both measurements together in the in the definition of diabetes. We therefore evaluated their combined use for this purpose against mean levels of hemoglobin A1c (HbA1c) in our patient groups. This was compared with the use of single cut-offs for either the 2hPG (WHO) or the FPG (ADA) respectively in the definition of diabetes.
The study was a diabetes clinic-based study on glucose intolerance in a small group of resident Kuwaiti and expatriate population in Kuwait. A random sample (n = 43) of visitors referred from a general clinic with a clinical suspicion of glucose intolerance or diabetes (unexplained constitutional symptoms in an appropriate setting [for example first degree relatives with diabetes] or symptoms of diabetes such as polyuria & polyphagia), aged 30 to 70 were included in the study. The OGTT was done by one of us (AP). Participants who were already treated for diabetes by insulin, oral anti-diabetic agents, or a physician-prescribed diet were excluded. Only 43 patients were recruited because we had allocated six months to data collection from the clinic. Patients are randomly allocated to each of five clinic physicians by the nursing staff and only new patients received by AP (n = 43 by six months) were included in this study.
Glucose, HbA1c and BMI measurements
After 8–10 hours of overnight fasting, blood was collected for the measurement of FPG. Subsequently, a 75-g oral glucose (glucose tolerance test beverage, Fisher healthcare, Curtin Matheson Scientific, Houston, Texas, USA) tolerance test (OGTT) was performed and the plasma glucose level was measured 2 hours later (2hPG). The glucose levels were determined by means of the oxygen rate method employing a Beckman Coulter Oxygen Electrode (glucose oxidase method, Beckman Coulter Inc, Galway, Ireland). HbA1c was measured by the Beckman Synchron LX system(Beckman Instruments Inc, Fullerton CA, 92834-3100). This utilizes two cartridges, Hb and A1c to determine A1c concentration as a percentage of total Hb. The hemoglobin is measured by a colorimetric method and the A1c concentration by a turbidimetric immunoinhibition method. The normal range for the HbA1c in our lab is 4.3–5.9%. Weight and height were measured with participants wearing light clothing only, and the body mass index (BMI) was calculated as weight divided by the square of the height (kg/m2).
Diagnosis of glycemic status
a) Single criteria
Diabetes was diagnosed if the 2hPG was 11.1 mmol/L or greater, or the FPG was 7.0 mmol/L or greater. Impaired fasting glucose (IFG) was defined as a FPG between 6.1 mmol/L and 6.9 mmol/L and IGT was diagnosed if the 2hPG was between 7.8 mmol/L and 11 mmol/L.
b) Our combined criteria
For the combined criteria the upper limit for the FPG (specific test) was combined with the lower limit for the 2hPG (sensitive test). Normality was based on the 2hPG value (<7.8 mmol/L) so long as the fasting value was concordant (<7 mmol/L). In the same way, a fasting value was used to define diabetes (≥ 7 mmol/L) so long as the 2hPG value was concordant (≥ 7.8 mmol/L). A discordant fasting and 2hPG value defines combined criteria IGT (cIGT).
All basic statistical analyses were done with Epi-info 6.04d  which was also the database with a cutoff for statistical significance of 0.05. Graphics were charted on SPSS version 10 for Windows, SPSS Inc, 1999. 95% confidence intervals for the difference in means was calculated using Statgraphics Plus for Windows version 3.0, Statistical Graphics Corporation.
The mean HbA1c (and 95% CI for the difference between means) of 2hPG or FPG subgroups within the combined criteria groups are reported. There were no significant differences in mean HbA1c between subgroups suggesting that the glycemic status within combined criteria groups was similar even for different FPG or 2hPG levels.
The difference in mean HbA1c and 95% confidence intervals for the difference between the means for the fasting and impaired subgroups of all three classification methods are reported. The implications of these differences are discussed in the text.
Difference and 95% CI for difference in means
0.7 (-0.15–1.57), p = 0.1
1.7 (0.79–2.69), p = 0.0007
1.2 (0.4 – 2), p = 0.003
Cutoff points such as those decided on by the ADA or WHO, allow the comparison of a dichotomy of a test variable against a relevant clinical endpoint. The test result however should be considered diagnostic of diabetes only if it separates those at a low and high risk for a clinically important outcome such as a specific microvascular or macrovascular complication. For example, the inherent risk for retinopathy, as demonstrated in epidemiological studies, was the rationale behind the derivation of the 2hPG of 11.1 mmol/L criterion . As the the HbA1c level at values ≥ 1% above the upper limit of normal (ULN) is associated with much greater development of progression of diabetic retinopathy or microalbuminuria, [21–24] its value correlates well with microvascular complications and was the standard in this study against which the various groups were evaluated. It may be pointed out here that although the use of the HbA1c in this way is useful (to define the glycemic status of patient groups with similar characteristics), it is not suitable for diabetes screening in individuals and cannot replace plasma glucose. It is true that the level of HbA1c is higher among diabetic than among nondiabetic persons, and among diabetic persons there is a correlation between HbA1c and various measures of glycemia, but this correlation seen in groups of patients does not hold for mildly hyperglycemic patients where the correlation is very poor, probably because glycemia proceeds at a slow rate and cannot reflect glycemia in toto . When the HbA1c has been used as a screening test for individual patients, as expected, it has an unacceptably low sensitivity  that results in very poor discrimination of normality, IGT and diabetes in individual patients. It has a good specificity , however, allowing its use for assessment of glycemic control in the follow-up of diabetics.
Our results first demonstrate that IGT and diabetes by the 2hPG are unable to distinguish different levels of HbA1c (table 2), suggesting excessive overlap of these two groups. This is corroborated by other studies where approximately two thirds of individuals diagnosed as having diabetes by a 2hPG concentration of 11.1–13.3 mmol/L on an oral glucose tolerance test have normal HBA1C levels . In addition to such normal HBA1C levels, less than 5% will have HbA1C levels ≥ 1% above the ULN that predicts an adverse outcome. Therefore, 95% of these patients will have met the American Diabetic Association's goal HbA1c value of less than the upper limit of normal + 1%  and will be treated with diet and exercise rather than pharmacological agents. This is the same treatment that would be offered to patients with impaired glucose tolerance, (i.e., those whose 2hPG concentrations on an oral glucose tolerance test are 7.8–11.0 mmol/L). This is also corroborated by pooled data in 16 studies presented by Davidson et al  where patients with an HbA1c level ≥ 1% above the ULN have been shown to have a very high probability of meeting the 2hPG criteria for diabetes (>95%) while at the same time (as noted above) most of the subjects with diagnostic 2hPG do not have a HbA1c ≥ 1% of the ULN and approximately two-thirds would actually have a normal HbA1c.
Secondly, we have also demonstrated that the HbA1c in those with IFG is very distinct from diabetics (by FPG, table 2). This is because a lot of the IFG group actually have normal glucose tolerance, making the separation from diabetics even more. This conclusion is supported by a 6 year prospective study of 1342 non-diabetic white Dutch individuals aged 50–75 years who had an OGTT at baseline and where IFG was present in only 28% of those with IGT but was absent in 92% of those without IGT (28% sensitivity, 92% specificity). Based on the usual prevalence of IGT and diabetes in communities, two-thirds of those with IFG can be expected to have a normal OGTT. This conclusion is also supported by the data presented by Davidson et al , where only about 13% of individuals diagnosed to have IFG by virtue of a FPG of 6.1–6.9 mmol/L will have an abnormal HbA1c. Less than 1% will have HbA1c levels ≥ 1% above the ULN. Therefore 87% of these persons should require no intervention. These authors (adapted from the table) also reveal that patients with a normal HbA1c have a very low probability (3%) of meeting the fasting threshold of 7 mmol/L. (This is in stark contrast to the people with FPG concentrations of 7.0 or more, two-thirds of whom have abnormal glycated hemoglobin levels )
What are the implications of this? It is clear that the FPG <7 mmol/L provides no reliable information on whether an individual is normal or is at risk from future diabetes or future cardiovascular, eye or kidney disease related to diabetes. In a similar fashion, the 2hPG provides poor discrimination of those at future risk from the overtly diabetic patients with ongoing risk. This is again confirmed by the Funagata Diabetes Study in Japan, where the hazard ratios for all cause and cardiovascular mortality were higher for subjects diagnosed with diabetes according to the FPG than for subjects diagnosed according to the 2hPG. However subjects with IGT had a higher risk of cardiovascular mortality than subjects with IFG. These observations suggest that a diagnostic fasting value represents a level of glycemia that provides a high level of clinical certainty that the patient does indeed have diabetes, especially if it is elevated on two occasions , whereas the 2-hour criterion does not. In the same vein, a normal 2hPG provides a high level of clinical certainty that a patient needs no intervention, whearas the fasting criterion does not. It then becomes clear that to diagnose normality, impaired glucose tolerance and diabetes, we need a combination of these two criteria: One that favours sensitivity to exclude diabetes and the other that favours specificity to diagnose diabetes. The same result can not be achieved by adjusting cut-offs of single measurements.
We acknowledge that our study is limited by the small number of participants. It is possible that in table 2, non-significance with the 2hPG could be related to the small number of patients. Nevertheless, the analysis in our combined criteria group had the same number of patients and this was even less in the FPG group but both reached statistical significance. In table 1, there were even smaller numbers compared in the cIGT groups, and it is possible that larger numbers may have attained a significant difference. This however seems unlikely for the FPG group where the mean difference was almost 1% higher in the normal group. We have cited the data in the literature extensively with our results, and the results from larger studies are not divergent from our data. Certainly, a larger trial is warranted to confirm the validity of this diagnostic approach.
Proposed combined criteria for the definition diabetes and impaired glucose tolerance. As expected in view of the small cohort, 100% of our patients with IGT by combined criteria had IGT1. This would mean that FPG diabetics and 2hPG normals will have 100% concordance with the combined criteria diabetics and normals respectively (see figure). In larger cohorts there may be a minor discordance of FPG diabetics and 2hPG normals with the combined criteria (IGT2).
Combined diagnostic criteria for diabetes
FPG≥ 7 mmol/L AND 2-hour glucose ≥ 7.8 mmol/L
Impaired glucose tolerance
IGT1: FPG<7 mmol/L AND 2-hour glucose ≥ 7.8 mmol/L Or IGT2: FPG≥ 7 mmol/L AND 2-hour glucose <7.8 mmol/L
FPG<7 mmol/L AND 2-hour glucose <7.8 mmol/L
- Valleron AJ, Eschwege E, Papoz , Rosselin GE: Agreement and discrepancy in the evaluation of normal and diabetic oral glucose tolerance test. Diabetes. 1975, 24: 585-93.View ArticlePubMedGoogle Scholar
- National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979, 28: 1039-57.View ArticleGoogle Scholar
- World Health Organization Expert Committee on Diabetes Mellitus: Second Report: Geneva, Switzerland: World Health Organization, Technical Report 646. 1980Google Scholar
- Jarrett RJ, Keen H: Hyperglycemia and diabetes mellitus. Lancet. 1976, 2: 1009-12. 10.1016/S0140-6736(76)90844-8.View ArticlePubMedGoogle Scholar
- Sayegh HA, Jarrett RJ: Oral glucose-tolerance test and the diagnosis of diabetes: results of a prospective study based on the Whitehall survay. Lancet. 1979, 2: 431-3. 10.1016/S0140-6736(79)91489-2.PubMedGoogle Scholar
- Pettitt DJ, Knowler WC, Lisse JR, Bennett PH: Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet. 1980, 2: 1050-2. 10.1016/S0140-6736(80)92274-6.View ArticlePubMedGoogle Scholar
- Davidson MB, Peters AL, Schriger DL: An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care. 1995, 18: 1065-71.View ArticlePubMedGoogle Scholar
- Committee Expert: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997, 20: 1183-97.View ArticleGoogle Scholar
- Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes. 1987, 36: 523-34.View ArticlePubMedGoogle Scholar
- Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care. 1998, 21: 1236-39.View ArticlePubMedGoogle Scholar
- Shaw JE, de Courten M, Boyko EJ, Zimmet PZ: Impact of new diagnostic criteria for diabetes on different populations. Diabetes Care. 1999, 22: 762-6.View ArticlePubMedGoogle Scholar
- The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia. 1999, 42: 647-54. 10.1007/s001250051211.View ArticleGoogle Scholar
- Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G: Risk of diabetes in the new diagnostic category of impaired fasting glucose. Diabetes Care. 1999, 22: 1490-93.View ArticlePubMedGoogle Scholar
- Shaw JE, Zimmet PZ, De Couten M, Dowse GK, Chiston P, Gareboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: Impaired fasting glucose or impaired glucose tolerance?. Diabetes Care. 1999, 22: 399-402.View ArticlePubMedGoogle Scholar
- The DECODE Study Group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and mortality: Comarison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999, 354: 617-21. 10.1016/S0140-6736(98)12131-1.View ArticleGoogle Scholar
- Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia. 1999, 42: 1050-54. 10.1007/s001250051269.View ArticlePubMedGoogle Scholar
- Olga Vaccaro, Gianluca Ruffa: Is There Any Use for the Oral Glucose Tolerance Test?. Diabetic Care. 2000, 23: 714-15.Google Scholar
- Gerstein HC: Fasting Versus Postload Glucose Levels: Why the controversy?. Diabetes Care. 2001, 24: 1855-7.View ArticlePubMedGoogle Scholar
- Dean AG, Dean JA, Coulombier D: Epi Info version 6: A word-processing, database and statistics program for public health on IBM-compatible microcomputers. Centers for Disease Control and Prevention, Atlanta, Georgia,. 1995Google Scholar
- David McCance R, Robert Hanson L: Which Test for Diagnosing Diabetes?. Diabetes Care. 1995, 18: 1042-44.View ArticleGoogle Scholar
- The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995, 44: 968-83.View ArticleGoogle Scholar
- Krowleski AS, Laffel LMB, Krowleski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995, 332: 1251-5. 10.1056/NEJM199505113321902.View ArticleGoogle Scholar
- Ohkubo Y, Kishikawa H, Araki E: Intensive insulin therapy prevents the progression of diabetic micro vascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995, 28: 103-17. 10.1016/0168-8227(95)01064-K.View ArticlePubMedGoogle Scholar
- Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R: Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998, 21: 116-20.View ArticlePubMedGoogle Scholar
- Service FJ: Correlation between glycemia and glycated hemoglobin. Comprehensive Therapy. 1990, 16: 33-40.PubMedGoogle Scholar
- Guillausseau PJ, Charles M-A, Paolaggi F, Timsit J, Chanson P, Peynet J, Godard V, Eschwege E, Rousselet F, Lubetzki J: Comparison of HbA1 and fructosamine in diagnosis of glucose-tolerance abnormalities. Diabetes Care. 1990, 13: 898-900.View ArticlePubMedGoogle Scholar
- Mayer Davidson B, David Schriger L: Revisiting the Oral Glucose Tolerance Test Criterion for the Diagnosis of Diabetes,. J Gen Intern Med. 2000, 15: 551-55. 10.1046/j.1525-1497.2000.08024.x.View ArticlePubMed CentralGoogle Scholar
- American Diabetic Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1999, 22 (suppl 1): S32-41.Google Scholar
- Davidson MB, Schriger DL, Peters AL, Lorber B: Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. J Gen Intern Med. 2000, 15: 551-555. 10.1046/j.1525-1497.2000.08024.x.View ArticlePubMedPubMed CentralGoogle Scholar
- de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001, 285: 2109-13. 10.1001/jama.285.16.2109.View ArticlePubMedGoogle Scholar
- Davidson MB, Schriger DL, Peters AL, Lorber B: Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999, 281: 1203-10. 10.1001/jama.281.13.1203.View ArticlePubMedGoogle Scholar
- Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999, 22: 920-4.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6823/2/1/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.